Abstract
Malignant gliomas are the most common primary brain tumors. Despite efforts to find effective treatments, these tumors remain incurable. The failure of malignant gliomas to respond to conventional cancer therapies may reflect the unique biology of these tumors, underscoring the need for new approaches in their investigation. Recently, progress has been made in characterization of the molecular pathogenesis of glioblastoma using a developmental neurobiological perspective, by exploring the role of signaling pathways that control the differentiation of neural stem cells along the glial lineage. The transcription factor STAT3, which has an established function in neural stem cell and astrocyte development, has been found to play dual tumor suppressive and oncogenic roles in glial malignancy depending on the mutational profile of the tumor. These findings establish a novel developmental paradigm in the study of glioblastoma pathogenesis and provide the rationale for patient-tailored therapy in the treatment of this devastating disease.
Current Molecular Medicine
Title: STAT3 Regulation of Glioblastoma Pathogenesis
Volume: 9 Issue: 5
Author(s): Nuria de la Iglesia, Sidharth V. Puram and Azad Bonni
Affiliation:
Abstract: Malignant gliomas are the most common primary brain tumors. Despite efforts to find effective treatments, these tumors remain incurable. The failure of malignant gliomas to respond to conventional cancer therapies may reflect the unique biology of these tumors, underscoring the need for new approaches in their investigation. Recently, progress has been made in characterization of the molecular pathogenesis of glioblastoma using a developmental neurobiological perspective, by exploring the role of signaling pathways that control the differentiation of neural stem cells along the glial lineage. The transcription factor STAT3, which has an established function in neural stem cell and astrocyte development, has been found to play dual tumor suppressive and oncogenic roles in glial malignancy depending on the mutational profile of the tumor. These findings establish a novel developmental paradigm in the study of glioblastoma pathogenesis and provide the rationale for patient-tailored therapy in the treatment of this devastating disease.
Export Options
About this article
Cite this article as:
la Iglesia de Nuria, Puram V. Sidharth and Bonni Azad, STAT3 Regulation of Glioblastoma Pathogenesis, Current Molecular Medicine 2009; 9 (5) . https://dx.doi.org/10.2174/156652409788488739
DOI https://dx.doi.org/10.2174/156652409788488739 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mast Cells and Inflammatory Heart Disease: Potential Drug Targets
Cardiovascular & Hematological Disorders-Drug Targets Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry The Effects of Colchicum baytopiorum on Regulatory Genes of Apoptotic and Autophagic Cell Death in HeLa Cells
Current Pharmaceutical Biotechnology Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands
Current Medicinal Chemistry Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry State-of-the-Art Magnetic Resonance Spectroscopy in Oncologic Imaging
Current Molecular Imaging (Discontinued) Thalidomide Analogues as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Endothelin-1 and Angiogenesis in Cancer
Current Vascular Pharmacology MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Lipid-based Nanocarriers As An Alternative for Oral Delivery of Poorly Water- Soluble Drugs: Peroral and Mucosal Routes
Current Medicinal Chemistry The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion
Current Cancer Drug Targets Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature
Current Drug Targets MicroRNAs Patents: The Road From Bench to Bedsides for Cancer Treatment
Recent Patents on DNA & Gene Sequences The Role of miR-129-5p in Cancer: A Novel Therapeutic Target
Current Molecular Pharmacology An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
Current Drug Delivery Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Current Medicinal Chemistry